Conselho Nacional de Desenvolvimento CientÃfico e TecnolÃgico / IntroduÃÃo: As drogas quimioterÃpicas convencionais nÃo tÃm obtido sucesso no tratamento do cÃncer gÃstrico. O paclitaxel (TaxolÂ) mostrou ser efetivo no tratamento dos cÃnceres de ovÃrio, mama e pulmÃo. O 5-fluorouracil (5-FU) tem apresentado resultados promissores no tratamento do cÃncer de cÃlon. O Ãcido folÃnico (LeucovorinÂ) potencializa a citotoxicidade do 5-fluorouracil. Estudos desen-volvidos no JapÃo, Estados Unidos e Europa vÃm sugerindo o uso de quimioterapia associada à hiper-termia no controle da doenÃa localmente avanÃada. Objetivos: Avaliar a influÃncia do paclitaxel, 5-fluorouracil e 5-fluorouracil mais Ãcido folÃnico, isolados e associados à hipertermia, na sobrevida de ratos com tumor de Walker 256 implantados no estÃmago, e observar o comportamento do tumor de Walker 256 original implantado em estÃmagos de rato sem tratamento e submetidos aos tratamentos quimioterÃpicos propostos, associados à hipertermia. MÃtodos: Implantou-se o tumor de Walker 256 na mucosa gÃstrica de rato no 3o, 7o, e 10o dias de inoculaÃÃo do tumor. Os animais foram tratados com paclitaxel, 5-fluorouracil e 5-fluorouracil mais Ãcido folÃnico, isolados e associados à hipertermia. Foram administrados paclitaxel na dose de 25 mg/m2, 5-fluorouracil na dose de 130 mg/m2 e Ãcido folÃnico na dose de 7 mg/m2. A Hipertermia de Corpo Inteiro foi iniciada 2 horas apÃs a administraÃÃo dos quimioterÃpicos, tendo duraÃÃo de 1 hora. Resultados: Os animais inoculados com tumor apresentaram uma sobrevida de 13,25  0,53. Os animais tratados com Paclitaxel isolado apresentaram sobrevida de 28,61  0,82; 20,92  1,77 e 20,07  0,60 no 3o, 7o e 10o dias, respectivamente, e aqueles trata-dos com Paclitaxel + hipertermia apresentaram sobrevida de 19,17  1,20; 22,54  1,47 e 17,92  1,06 nos mesmos perÃodos. Os animais tratados com 5-fluorouracil isolado apresentaram sobrevida de 16,16  0,52; 15,57  0,57 e 17,94  0,46 no 3o, 7o e 10o dias, respectivamente, e aqueles tratados com 5-fluorouracil + hipertermia apresentaram sobrevida de 14,45  0,36; 16,36  0,81 e 18,37  1,86 nos mesmos perÃodos. Os animais tratados com 5-fluorouracil + Ãcido folÃnico apresentaram sobrevida de 14,89  0,71; 16,56  0,91 e 16,11  0,67 no 3o, 7o e 10o dias, respectivamente, e aqueles tratados com 5-fluorouracil + Ãcido folÃnico + hipertermia apresentaram sobrevida de 17,60  1,22; Â15,42  0,31 e 15,45  0,39 nos mesmos perÃodos. ConclusÃes: O tumor experimental de Walker 256 à um tumor de pequenas cÃlulas. A hipertermia associada à quimioterapia, com paclitaxel, 5-fluorouracil, 5-fluorouracil mais Ãcido folÃnico como tratamento do tumor de Walker experimental implantado nos estÃmagos de rato Wistar, nÃo melhorou a sobrevida. / Introduction: The conventional chemotherapy drugs have not obtained success on the treatment of gastric cancer. The paclitaxel (TaxolÂ) showed to be effective on treating lung, breast and ovarian cancer. The 5-fluorouracil (5-FU) has shown promising results on the treatment of colon cancer. The folinic acid (LeucovorinÂ) reinforces the 5-FU cytotoxicity. Studies developed in Japan, United States and Europe suggest the use of chemotherapy associated with hyperthermia on the control of locally advanced disease. Objectives: Evaluate the influence of paclitaxel, 5-fluorouracil and 5-fluorouracil plus folinic acid, isolated and associated with hyperthermia, on the survival of rats with Walker 256 tumor implanted on their stomach, and observe the behavior of the original Walker 256 tumor implanted in the stomach of rats with no treatment and with the proposed chemotherapy treatments associated with hyperthermia. Methods: The Walker 256 tu-mor was implanted on the mucous layer of the rat stomach on the 3rd, 7th and 10th day after inoculation. The animals were treated with paclitaxel, 5-fluorouracil and 5-fluorourcil plus folinic acid isolated and associated with hyperthermia. Paclitaxel 25 mg/m2, 5-fluorouracil 130 mg/m2 and folinic acid 7 mg/m2 were used. The Whole-Body Hyperthermia was initiated 2 hours after the administration of the chemotherapic drugs, with 1 hour of duration. Results: The animals in-oculated with tumor showed a survival of 13.25  0.53. The animals treated with Paclitaxel isolated showed a survival of 28.61  0.82; 20.92  1.77 and 20.07  0.60 in the 3rd, 7th and 10th days, respectively, and those treated with Paclitaxel + hyperthermia showed a survival of 19.17  1.20; 22.54  1.47 and 17.92  1.06 in the same periods. The animals treated with 5-fluorouracil isolated showed a survival of 16.16  0.52; 15.57  0.57 and 17.94  0.46 in the 3rd, 7th and 10th days, respectively, and those treated with 5-fluorouracil + hyperthermia showed a survival of 14.45  0.36; 16.36  0.81 and 18.37  1.86 in the same periods. The animals treated with 5-fluorouracil + folinic acid showed a survival of 14.89  0.71; 16.56  0.91 and 16.11  0.67 in the 3rd, 7th and 10th days, respectively, and those treated with 5-fluorouracil + folinic acid + hyperthermia showed a survival of 17.60  1.22; 15.42  0.31 and 15.45  0.39 in the same periods. Conclusions: The Walker 256 is a small cell tumor. The hyperthermia associated with chemotherapy using pacli-taxel, 5-fluorouracil and 5-fluorouracil plus folinic acid as treatment of Walker experimental tu-mor implanted in Wistar rat stomachs do not improved the survival.
Identifer | oai:union.ndltd.org:IBICT/oai:www.teses.ufc.br:464 |
Date | 09 October 2003 |
Creators | Paulo Ferdinando de Melo Oliveira |
Contributors | Manoel Odorico de Moraes Filho, Ronaldo de Albuquerque Ribeiro, Lusmar Veras Rodrigues, Paulo Roberto LeitÃo de Vasconcelos, Francisco Valdeci de Almeida Ferreira |
Publisher | Universidade Federal do CearÃ, Programa de PÃs-GraduaÃÃo em Farmacologia, UFC, BR |
Source Sets | IBICT Brazilian ETDs |
Language | Portuguese |
Detected Language | English |
Type | info:eu-repo/semantics/publishedVersion, info:eu-repo/semantics/doctoralThesis |
Format | application/pdf |
Source | reponame:Biblioteca Digital de Teses e Dissertações da UFC, instname:Universidade Federal do Ceará, instacron:UFC |
Rights | info:eu-repo/semantics/openAccess |
Page generated in 0.0073 seconds